Cardiac-specific overexpression of caveolin-3 preserves t-tubular ICa during heart failure in mice

Cherrie H T Kong1, Simon M Bryant1, Judy J Watson1

  • 1School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.

Experimental Physiology
|February 21, 2019
PubMed

Insights

Overexpression of caveolin-3 (Cav-3 OE) in mice offers limited protection against heart failure by reducing cellular hypertrophy and preserving t-tubule calcium current, but does not fully restore calcium release.

Area of Science:

  • Cardiovascular Biology
  • Cellular Physiology
  • Molecular Cardiology

Background:

  • Caveolin-3 (Cav-3) is crucial for cardiac t-tubule function.
  • Cav-3 expression decreases during cardiac hypertrophy and failure, impairing excitation-contraction coupling.
  • Previous studies suggested Cav-3 overexpression (OE) is cardio-protective, but its cellular effects in heart failure were unknown.

Purpose of the Study:

  • To investigate the protective effects of Cav-3 OE against cellular changes induced by pressure overload in mouse hearts.
  • To determine if Cav-3 OE can prevent or mitigate hypertrophy, t-tubule disruption, and impaired calcium handling in heart failure.

Main Methods:

  • Induced pressure overload heart failure in mice using transverse aortic constriction (TAC) for 8 weeks.
  • Compared cardiac and cellular responses between Cav-3 OE mice and wild-type (WT) mice.
  • Assessed cardiac function, hypertrophy, t-tubule structure, and calcium handling (t-tubular ICa and Ca2+ release).

Main Results:

  • Cav-3 OE mice showed reduced cardiac and cellular hypertrophy compared to WT mice following TAC.
  • T-tubular calcium current (ICa) density was preserved in Cav-3 OE mice.
  • Despite preserved ICa, local t-tubular Ca2+ release remained impaired in Cav-3 OE mice after TAC.

Conclusions:

  • Cav-3 OE provides specific but limited protection against pressure overload-induced heart failure.
  • Cav-3 OE mitigates cardiac and cellular hypertrophy and preserves t-tubular calcium current.
  • Other factors beyond Cav-3 levels contribute to the disruption of local calcium release in heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272